GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiadis Pharma NV (XAMS:KDS) » Definitions » Asset Turnover

Kiadis Pharma NV (XAMS:KDS) Asset Turnover : 0.27 (As of Dec. 2020)


View and export this data going back to 2015. Start your Free Trial

What is Kiadis Pharma NV Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Kiadis Pharma NV's Revenue for the six months ended in Dec. 2020 was €17.50 Mil. Kiadis Pharma NV's Total Assets for the quarter that ended in Dec. 2020 was €65.44 Mil. Therefore, Kiadis Pharma NV's Asset Turnover for the quarter that ended in Dec. 2020 was 0.27.

Asset Turnover is linked to ROE % through Du Pont Formula. Kiadis Pharma NV's annualized ROE % for the quarter that ended in Dec. 2020 was 4,736.94%. It is also linked to ROA % through Du Pont Formula. Kiadis Pharma NV's annualized ROA % for the quarter that ended in Dec. 2020 was -192.83%.


Kiadis Pharma NV Asset Turnover Historical Data

The historical data trend for Kiadis Pharma NV's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiadis Pharma NV Asset Turnover Chart

Kiadis Pharma NV Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Asset Turnover
Get a 7-Day Free Trial Premium Member Only - - - - 0.25

Kiadis Pharma NV Semi-Annual Data
Dec12 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.27

Competitive Comparison of Kiadis Pharma NV's Asset Turnover

For the Biotechnology subindustry, Kiadis Pharma NV's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiadis Pharma NV's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiadis Pharma NV's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Kiadis Pharma NV's Asset Turnover falls into.



Kiadis Pharma NV Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Kiadis Pharma NV's Asset Turnover for the fiscal year that ended in Dec. 2020 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2020 )/( (Total Assets (A: Dec. 2019 )+Total Assets (A: Dec. 2020 ))/ count )
=17.5/( (79.502+62.762)/ 2 )
=17.5/71.132
=0.25

Kiadis Pharma NV's Asset Turnover for the quarter that ended in Dec. 2020 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2020 )/( (Total Assets (Q: Jun. 2020 )+Total Assets (Q: Dec. 2020 ))/ count )
=17.5/( (68.122+62.762)/ 2 )
=17.5/65.442
=0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Kiadis Pharma NV  (XAMS:KDS) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Kiadis Pharma NV's annulized ROE % for the quarter that ended in Dec. 2020 is

ROE %**(Q: Dec. 2020 )
=Net Income/Total Stockholders Equity
=-126.192/-2.664
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-126.192 / 35)*(35 / 65.442)*(65.442/ -2.664)
=Net Margin %*Asset Turnover*Equity Multiplier
=-360.55 %*0.5348*-24.5653
=ROA %*Equity Multiplier
=-192.83 %*-24.5653
=4,736.94 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2020) net income data. The Revenue data used here is two times the semi-annual (Dec. 2020) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Kiadis Pharma NV's annulized ROA % for the quarter that ended in Dec. 2020 is

ROA %(Q: Dec. 2020 )
=Net Income/Total Assets
=-126.192/65.442
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-126.192 / 35)*(35 / 65.442)
=Net Margin %*Asset Turnover
=-360.55 %*0.5348
=-192.83 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2020) net income data. The Revenue data used here is two times the semi-annual (Dec. 2020) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Kiadis Pharma NV Asset Turnover Related Terms

Thank you for viewing the detailed overview of Kiadis Pharma NV's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Kiadis Pharma NV (XAMS:KDS) Business Description

Traded in Other Exchanges
N/A
Address
Paasheuvelweg 25A, Amsterdam, NLD, 1105 BP
Kiadis Pharma NV is a Netherlands based clinical-stage biopharmaceutical company. It is focused on research, development, and commercialization of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company's product pipeline includes K-NK002, K-NK003, K-NK00X, and others.

Kiadis Pharma NV (XAMS:KDS) Headlines

No Headlines